Bellicum Pharmacueticals Inc. (BLCM) Stock Price Up 2%
Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) rose 2% during trading on Friday . The stock traded as high as $13.89 and last traded at $13.77, with a volume of 136,440 shares trading hands. The stock had previously closed at $13.50.
BLCM has been the subject of several recent research reports. SunTrust Banks Inc. initiated coverage on shares of Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price for the company. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research note on Monday, July 11th. Finally, Piper Jaffray Cos. reissued a “buy” rating on shares of Bellicum Pharmacueticals in a research note on Saturday, July 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.00.
The company’s 50 day moving average is $13.01 and its 200 day moving average is $11.44. The stock’s market capitalization is $371.70 million.
Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. Analysts forecast that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.
In other Bellicum Pharmacueticals news, CTO Kevin M. Slawin sold 55,000 shares of the firm’s stock in a transaction dated Friday, April 22nd. The shares were sold at an average price of $11.43, for a total value of $628,650.00. Following the completion of the sale, the chief technology officer now owns 159,206 shares in the company, valued at approximately $1,819,724.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ken Moseley sold 15,000 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the vice president now owns 15,196 shares of the company’s stock, valued at approximately $197,548. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley increased its stake in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.